Debt and warrant offering · Healthtech

BioVentrix reports $1.2 million sold in debt and warrant offering

The heart failure device developer disclosed six investors in an offering targeting $3 million.

BioVentrix reported $1.2 million in securities sold to six investors in a Form D filed on October 8, 2026. The offering lists debt, options or warrants, and securities issuable on exercise or conversion.

The first sale occurred on September 29. The $3 million offering target left $1.8 million unsold at filing. The notice does not identify the investors or specify a financing stage or conversion terms.

The Mansfield, Massachusetts company develops the Revivent System for remodeling the damaged left ventricle in patients with heart failure. Its current clinical program includes the randomized RELIVE trial; the device remains investigational in the United States.

Funding history

Debt and warrant offering · This round$1.2M

Sources

  1. BioVentrix and Revivent investigational therapybioventrix.com
  2. BioVentrix new debt offeringsec.gov · Oct 8, 2026